Sigi

DoseMe Fuels Global Expansion with Appointment of Siegfried Bräuer to Director International Sales

Retrieved on: 
Wednesday, January 31, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Siegfried, Interim, Growth, TDM, Knowledge, Sigi, MBA, MEA, Medicine, Merck, Emory University, Johannes Kepler University Linz

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the appointment of Siegfried Bräuer to Director, International Sales.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the appointment of Siegfried Bräuer to Director, International Sales.
  • In this role, he will lead the expansion of DoseMe’s Model Informed Precision Dosing (MIPD) platform through channel partners and direct sales across multiple continents.
  • Siegfried Bräuer brings a wealth of experience in pharma with a long tenure at Merck.
  • DoseMe continues to focus on product innovation and go-to-market expansion to build new drug models to broaden the MTDM platform.

Mallinckrodt Announces Board of Directors and Leadership Updates

Retrieved on: 
Friday, February 2, 2024
Public, Genetics, Eli Lilly and Company, ExxonMobil, CFO, Eli Lilly, Patient, Teva Pharmaceuticals, Marketing, Executive Committee, Barr Pharmaceuticals, Sigi, Ecology, Morgan Stanley, Amneal Pharmaceuticals, Aspen Pharmacare, ViiV Healthcare, Employment, Bausch Health, GSK plc, The Company, Thermo Fisher Scientific, Therapy, Chairperson, KKR, Engineering, Management

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately. Mr. Bisaro has also been reappointed to his previous role as Board Chair. In addition, the Company announced that Siggi Olafsson has entered into a new employment agreement and will continue in his roles as Mallinckrodt's President and Chief Executive Officer and a member of the Board.

Key Points: 
  • Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
    Siggi Olafsson Will Continue as President, CEO and Board Member
    DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately.
  • Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt."
  • Select professional highlights of Mallinckrodt's new directors include:
    Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies.
  • With the appointment of Messrs Bisaro, Hussain and Wheeler and Ms. Dorton, Mallinckrodt's Board comprises seven directors.

Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

Retrieved on: 
Thursday, January 12, 2023
MannKind Corporation, R, Development, BM, Human resources, Financial compensation, Aptalis, Novartis, Safety, MRCP, NYSE, Research and development, Sigi, Eli Lilly and Company, BS, Patient, The Company, Executive Committee, SCI, Employment, Health, Pharmacy, Pharmaceutical industry, Mallinckrodt, Research

DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023.

Key Points: 
  • DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023.
  • He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in December 2022.
  • Dr. Richardson previously served as Executive Vice President, Head of Research and Development and Chief Medical Officer at Antares Pharmaceuticals, overseeing all pharmaceutical research and development activities across the organization.
  • "Peter is another strong addition to our Executive Committee, and I am very pleased that he is joining Mallinckrodt to lead our portfolio expansion efforts as Chief Scientific Officer," said Siggi Olafsson, President and Chief Executive Officer.

Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer

Retrieved on: 
Monday, September 19, 2022
Autoimmunity, Rheumatology, Risk, Commercial Operating System (COS), Organon, Sigi, West Chester University, Ophthalmology, Harvard Business School, U.S. Securities and Exchange Commission, HIV, Company, Nephrology, National Directorate of Intelligence and Prevention Services, Private Securities Litigation Reform Act, Analgesic, Immunotherapy, Patient, Women's health, National, Leadership, Popular Executive Committee of Valencia, Drug development, The Company, Record, Emergency Leaders for Climate Action, Neurology, Associate, Ajman Specialty General Hospital, Executive Committee, SEC, University, Management, Pharmaceutical industry, Mallinckrodt, Merck, Biology

DUBLIN, Sept. 19, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has appointed Lisa French as Executive Vice President and Chief Commercial Officer, effective October 1, 2022.

Key Points: 
  • DUBLIN, Sept. 19, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has appointed Lisa French as Executive Vice President and Chief Commercial Officer, effective October 1, 2022.
  • Ms. French will serve on the Executive Committee and succeeds Hugh O'Neill, who departed Mallinckrodt as of September 16, 2022.
  • Ms. French most recently built and led the U.S. Women's Health Commercial team for Organon & Co. following its spin-off from Merck.
  • Siggi Olafsson, President and Chief Executive Officer, said, "I am delighted to welcome Lisa to Mallinckrodt as our new Chief Commercial Officer and a member of our Executive Committee.

Lactalis Canada to Expand Plant-Based Offering with New Converted Production Facility in Sudbury, Ontario

Retrieved on: 
Wednesday, August 10, 2022
Diamond, Sigi, CEO, Black Diamond, Balderson, Growth, Forbes, Sustainability, Workforce, Dairy, Lactalis Canada, Cracker Barrel, IGO, Mother Dairy, CDN, Astro, Best Employers in Canada, Animal, Oil, Milk

This announcement follows Lactalis Canada's decision to cease milk processing and packaging at its Sudbury, Ontario plant effective September 30, 2022.

Key Points: 
  • This announcement follows Lactalis Canada's decision to cease milk processing and packaging at its Sudbury, Ontario plant effective September 30, 2022.
  • More details on Lactalis Canada's forthcoming expansion and product offering will be announced in the coming months.
  • With 140 years of brand heritage, Lactalis Canada is committed to enriching and nurturing the lives of Canadians by producing nutritious and great tasting dairy products.
  • Lactalis Canada is part of Lactalis Group, the world's leading dairy company, headquartered in Laval, France.

Cumulus Neuroscience appoints Siggi Saevarsson as COO

Retrieved on: 
Thursday, February 10, 2022
Science, Sigi, Intel, Openwave, Copenhagen Business School, DDF, Computer science, Time, Company, Cumulus cloud, CNS, Clinical trial, Neuroscience, HIV disease progression rates, Dementia, Patient, Central nervous system, Carnegie Mellon University, Neurodegeneration, LifeArc, Central Waqf Council, COO, Acquisition, Management, Medical imaging

BELFAST, Northern Ireland, Feb. 10, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing central nervous system (CNS) therapies, announces that Siggi Saevarsson has been appointed as Chief Operating Officer (COO).

Key Points: 
  • BELFAST, Northern Ireland, Feb. 10, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing central nervous system (CNS) therapies, announces that Siggi Saevarsson has been appointed as Chief Operating Officer (COO).
  • Cumulus Neuroscience CEO Ronan Cunningham commented:"We are delighted to bring Siggi on board at such an important time for Cumulus.
  • Siggi brings deep experience in scaling and growing high-technology companies and will play a pivotal role in ensuring that Cumulus realizes its full potential."
  • Siggi Saevarsson, newly appointed COO, added: "Cumulus has made fantastic progress and I am excited to be joining the company for the next stage of its evolution.

Cumulus Neuroscience appoints Siggi Saevarsson as COO

Retrieved on: 
Thursday, February 10, 2022
Science, Sigi, Intel, Openwave, Copenhagen Business School, DDF, Computer science, Time, Company, Cumulus cloud, CNS, Clinical trial, Neuroscience, HIV disease progression rates, Dementia, Patient, Central nervous system, Carnegie Mellon University, Neurodegeneration, LifeArc, Central Waqf Council, COO, Acquisition, Management, Medical imaging

BELFAST, Northern Ireland, Feb. 10, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing central nervous system (CNS) therapies, announces that Siggi Saevarsson has been appointed as Chief Operating Officer (COO).

Key Points: 
  • BELFAST, Northern Ireland, Feb. 10, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing central nervous system (CNS) therapies, announces that Siggi Saevarsson has been appointed as Chief Operating Officer (COO).
  • Cumulus Neuroscience CEO Ronan Cunningham commented:"We are delighted to bring Siggi on board at such an important time for Cumulus.
  • Siggi brings deep experience in scaling and growing high-technology companies and will play a pivotal role in ensuring that Cumulus realizes its full potential."
  • Siggi Saevarsson, newly appointed COO, added: "Cumulus has made fantastic progress and I am excited to be joining the company for the next stage of its evolution.

Amazon #1 Bestseller UNSTOPPABLE Declared 'Business Book of the Year'

Retrieved on: 
Wednesday, January 26, 2022
PricewaterhouseCoopers, NPR, The Holocaust, Gestapo, News, Persecution, Bank Holding Company Act, Discovery, Financial Times and McKinsey Business Book of the Year Award, Pentagon, List of presidents of the United States, Library Journal, CNN, PBS, Forbes, Poverty, The New York Times, Nazism, Sigi, United States Military Academy, Fox News, Courage, Fresh Air, Greene, Survival, Death, GLOBE, Federal, Federal Reserve, Entertainment, Pharmaceutical industry, Unstoppable, Amazon, Mauthausen concentration camp

It then quickly turns into a series of exciting tales that give the reader a sense of how his foxlike mind worked.

Key Points: 
  • It then quickly turns into a series of exciting tales that give the reader a sense of how his foxlike mind worked.
  • strategy+business states, "This compelling tale of suffering, persecution, and triumph is the best business book in the form of a historical narrative this year."
  • This and other interesting stories, like how Siggi came to meet not one but four sitting United States Presidents, are all detailed in the book.
  • He has appeared on national media outlets, from NPR's Fresh Air with Terry Gross to FOX News, CNN, and more.

AMF Medical Welcomes Diabetes Industry Executives John Timberlake and Peter Gerhardsson to Its Board of Directors

Retrieved on: 
Tuesday, November 9, 2021
Corporation, Corporate social responsibility, VP, Business, NEOMA Business School, Retirement, Northwest Missouri State University, Health, Rouen Business School, CEO, Institute, MBA, Technology, Linköping University, Medtronic, Dexcom, Insulin glargine, Purdue University, Insulin, Board, International business development, Novo Nordisk, Toxicology, Medicine, Board of directors, Sigi, Lund University, Diabetes, International business, Patient, BS, Medical device, Pharmaceutical industry, Management

ECUBLENS, Switzerland, Nov. 9, 2021 /PRNewswire/ -- Diabetes industry experts John Timberlake and Peter Gerhardsson have joined AMF Medical's Board of Directors.

Key Points: 
  • ECUBLENS, Switzerland, Nov. 9, 2021 /PRNewswire/ -- Diabetes industry experts John Timberlake and Peter Gerhardsson have joined AMF Medical's Board of Directors.
  • John Timberlake is a diabetes industry veteran and is well known for his successful healthcare executive leadership.
  • Mr. Timberlake is currently the CEO and a board member of Berkshire Biomedical Corporation.
  • Mr. Timberlake said, "The team at AMF Medical designed Sigi with a clear focus on making insulin pump use very simple, effective, and more accessible.